Swissmedic time-limited market approval in for Idefirix in kidney transplantation

13 May 2022

Swedish rare disease specialist Hansa Biopharma (STO: HNSA) today revealed that the Swiss Agency for Therapeutic Products (Swissmedic) has granted time-limited market approval for Idefirix (imlifidase) for adult patients with a positive cross-match against an accessible organ from a deceased donor.

The use of Idefirix in Switzerland is reserved for patients with a low probability of being transplanted under the current national kidney allocation system. The drug was approved by the European Commission in 2020.

" We want to ensure access to Idefirix for highly sensitized patients worldwide who are awaiting a potentially vital kidney transplant and are now pleased that, in addition to the market approvals already received in the EU, UK and Israel, we have also received approval in Switzerland," says Søren Tulstrup, chief executive and president of Hansa Biopharma.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK